Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission - including an outpatient dosing option using a single weight-based dose IND amendment ...
Stocktwits on MSN
BEAM stock in focus as FDA alignment wins William Blair’s praise
The company expects to submit a biologics license application for risto-cel by year-end 2026. ・Beam ended 2025 with an ...
The country moves into 2026 with a clearer sense of what it takes to build a steady, clean energy future. The shift underway ...
Quince Therapeutics (QNCX) rated Buy ahead of Phase 3 NEAT readout in A-T; eDSP targets $1B+ orphan market with strong cash ...
Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in all six patients with successful bronchoscopies irrespect ...
Immuneering Corporation stays a Strong Buy: pancreatic cancer combo shows 64% 12‑mo OS, strong safety, and clear catalysts ...
True patient-centricity will drive commercial success as CGT moves beyond first-generation therapies. Current timelines in CGT, from diagnosis to treatment, can exceed six months, often compounded by ...
Researchers analyzed the diagnostic value of stereotactic brain biopsy in patients with leukemia presenting central ...
The cell phone policy comes after several other school districts in the Triangle restricted cell phone and personal device ...
Over the last decade, PaCT has engaged more than 450 factories, catalysing 35 billion litres of freshwater savings and 29 billion litres of wastewater reduction per year, alongside 3.8 million ...
Under the proposed changes, 10 schools will lose some programs of study. Instead, students will have access to 16 courses at ...
The FDA has issued a complete response letter for the partners’ application in EBV+PTLD, marking the agency’s second snub of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback